Actively Recruiting
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Led by Vanda Pharmaceuticals · Updated on 2026-03-16
42
Participants Needed
11
Research Sites
478 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
CONDITIONS
Official Title
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of informed consent
- Confirmed relapsed or refractory malignant hematologic or lymphoid disease after standard therapy
- Measurable or evaluable disease present
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Use of contraceptives or approved pregnancy avoidance measures
You will not qualify if you...
- Active graft versus host disease or immunosuppression after allogeneic stem cell transplant
- Taking other anti-cancer therapies except bisphosphonates
- Major surgery within 2 weeks prior to starting the study drug
- Presence of mucosal or internal bleeding
- Impaired heart function or conduction problems
- Severe or uncontrolled medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Vanda Investigational Site
Washington D.C., District of Columbia, United States, 20007
Withdrawn
2
Vanda Investigational Site
Lafayette, Indiana, United States, 47905
Completed
3
Vanda Investigational Site
Hackensack, New Jersey, United States, 07601
Withdrawn
4
Vanda Investigational Site
Seattle, Washington, United States, 98109
Completed
5
Vanda Investigational Site
Biała Podlaska, Poland
Actively Recruiting
6
Vanda Investigational Site
Katowice, Poland
Actively Recruiting
7
Vanda Investigational Site
Krakow, Poland
Completed
8
Vanda Investigational Site
Opole, Poland
Actively Recruiting
9
Vanda Investigational Site
Skorzewo, Poland
Completed
10
Vanda Investigational Site
Warsaw, Poland
Actively Recruiting
11
Vanda Investigational Site
Wroclaw, Poland
Completed
Research Team
V
Vanda Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here